Plant-based Covid-19 vaccine developer Medicago laying off 60+ at North Carolina plant
2022-10-27
疫苗合作
Medicago had been looking at, among other things, a plant-based vaccine for Covid-19. But those plans aren’t going in the direction Medicago wanted to.
Medicago’s US subsidiary Medicago USA filed a WARN notice Wednesday in North Carolina, saying that 62 employees at its manufacturing facility in Durham will be out of a job within two months.
Medicago CEO Toshifumi Tada, who just recently joined the biotech earlier this year, told
Endpoints News
via email that:
Tada became CEO back in May, transitioning from head of vaccine business development at Medicago’s parent company, Mitsubishi Tanabe Pharma. This is the newest development for the vaccine maker after the WHO balked at Medicago’s Covid-19 vaccineCovid-19 vaccine earlier this year. Medicago partnered with GSK to use one of GSK’s adjuvants to boost immune response.
The international organization balked because of the biotech’s ties to Big Tobacco, more specifically Philip Morris International, the maker of Marlboro cigarettes and a part-owner of Medicago.
Many biotechs — and several pharmas — have had to pull out the trimmers in 2022 because of budget constraints and R&D mishaps. Biotechs include Zosano, which now
filed for bankruptcy
and is
selling off all of its assets
, after doing
two rounds of layoffs
in order to try and stay afloat. Or more recently Ambrx,
announcing
plans last week to cut 15% of staff in a bid to extend cash resources.
On the pharma side, AbbVie recently laid off 100 in California, right at the same time as Bristol Myers let go of 260 staffers as it was looking to integrate Turning Point Therapeutics into the fold.
Biogen also started laying off people in light of Aduhelm’s failure back in
March
. A senior official within the company told Endpoints at the time that more than 100 individuals have been laid off so far, including two-thirds of the Alzheimer’s commercial team and all of the Alzheimer’s field leaders.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。